康柏西普治疗息肉状脉络膜血管病变的临床疗效

目的　探讨康柏西普治疗息肉状脉络膜血管病变（polypoid choroidal vasculopathy，PCV）的效果。方法　以本院2015年5月至2016年5月收治的50例（50眼）PCV患者为研究对象，所有患者均接受玻璃体内注射康柏西普治疗，测定并记录患者不同时间点矫正视力（LogMAR）、黄斑中心凹厚度（central macular thickness，CMT）及眼压变化，并统计康柏西普注射次数、并发症、黄斑中心凹及息肉消退情况。结果　患者患眼注射1～4（2.85±0.50）次，均无眼压增高、眼内炎等并发症发生；治疗后12个月，LogMAR矫正视力为0.60±0.32，较术前（0.91±0.53）明显降低，差异有统计学意义（P＜0.05）；CMT为（310.53±39.62）μm，较治疗前［（400.21±56.35）μm］明显降低，差异有统计学意义（P＜0.05）。另外，有15例患者视力稳定，35例患者视力提高，视力提高率为70.00%。治疗前后眼压变化差异无统计学意义（P＞0.05）。结论　康柏西普能有效改善PCV患者视力，减轻黄斑水肿，且对眼压无明显影响。

Clinical efficacy of conbercept in the treatment of polypoidal choroidal vasculopathy

Objective　To investigate the effects of conbercept in the treatment of polypoidal choroidal vasculopathy （PCV）.Methods　50 patients （50 eyes） with PCV who were diagnosed and treated in the hospital from May 2015 to May 2016 were selected as the subjects，and they were treated with intravitreal injection of conbercept.Changes of corrected visual acuity （LogMAR），central macular thickness （CMT） and intraocular pressure at different time points were measured and recorded.The injection frequency of conbercept，complications，macular region and polyp regression were counted.Results　The injection frequency was 1-4 （2.85±0.50）times，and there were no complications of increased intraocular pressure or intraocular inflammation.The LogMAR corrected visual acuity at 12 months after treatment was significantly decreased compared with that before treatment ［（0.60±0.32） vs.（0.91±0.53）］（P<0.05）.The CMT was significantly decreased compared with that before treatment ［（310.53±39.62）μm vs.（400.21±56.35）μm］（P<0.05）.In addition，there were 15 patients with stable visual acuity and 35 patients with improved visual acuity，and the improvement rate of visual acuity was 70.00%.There was no significant difference in intraocular pressure before and after treatment （P>0.05）.Conclusion　Conbercept can effectively improve the visual acuity of patients with PCV and reduce macular edema，and it has no obvious effects on intraocular pressure.